Companies › Hope Biosciences Research Foundation
2 active drug programs in 2 registered trials: 2 Phase 2; Immunology, Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Autologous HB-adMSCs Autologous adipose-derived mesenchymal stem cells | – | Phase 2 | Relapsing Remitting Multiple Sclerosis (RRMS) | Jan 2027 |
| HB-adMSCs (Hope Biosciences Adipose Derived Mesenchymal Stem Cells) Allogeneic adipose-derived mesenchymal stem cells | – | Phase 2 | Crohn Disease (CD) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06800404 | Autologous HB-adMSCs | Phase 2 | Relapsing Remitting Multiple Sclerosis (RRMS) | Neurology | Jan 2027 |
| NCT07077746 | HB-adMSCs (Hope Biosciences Adipose Derived Mesenchymal Stem Cells) | Phase 2 | Crohn Disease (CD) | Immunology | Dec 2027 |
No annotated target.
–
Kyverna Therapeutics Autolus Nature Cell Throne Biotechnologies Nippon Shinyaku
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.